Aims: LEGIONE is a 34-week study that is evaluating whether an investigational medication called rozanolixizumab is well tolerated and effective in treating LGI1 autoimmune encephalitis. This drug is also being studied in other conditions that involve the immune system.

Institution:  This study is sponsored by UCB, a global biopharma company focusing on immunology and neurology disorders, including autoimmune diseases.

Location: LEGIONE will be taking place at sites in several different countries all around the world (Australia, Belgium, Canada, France, Germany, Italy, Korea, Netherlands, Portugal, Spain, Turkey, United Kingdom, USA). You can use this link below to search for the site closest to you and see their contact information.  

What key criteria should participants meet

  • Be between 18 and 89 years old
  • Have tested positive for anti-LGI1 antibody
  • Have symptoms that started within the last 12 months and include facio-brachial dystonic seizures (FBDS) and/or other partial (focal) seizures, unless they stopped as a result of current intravenous methylprednisolone (IVMP) treatment
  • Be considered suitable for treatment with IVMP or have started treatment with IVMP

What will taking part involve for the participants?

The study will take place over 34 weeks and includes screening ( finding out if you are suitable for the study), study treatment period and safety follow-up period (monitoring).

Clinical studies are completely voluntary, and participants can leave at any time without losing any benefits they would normally be entitled to.

Will participant expenses be reimbursed?                                                           

You will be reimbursed for reasonable travel expenses as appropriate.

If you are interested in taking part, or you think someone you care about may be suitable for the study, talk to your doctor. They may be able to discuss the study with you and talk you through the potential benefits and risks of being involved before you make your decision about participating.

Alternatively, please check contact details for the closest site and get in touch

 For more information about the study